This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.
Age 18 years or older at the time of signing the informed consent form (ICF).
For Phase 1b: Dynamic International Prognostic Scoring System (DIPSS) score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to World Health Organization (WHO) 2016 criteria.
Androgens
EPO
Hereditary hemochromatosis
Hemoglobinopathy or intrinsic RBC defect associated with anemia
Total splenectomy
Hematopoietic cell transplant within the past 2 years, or graft vs host disease requiring immunosuppression